4th How I Manage
CAR-T Therapies and Bispecific Antibodies for my Patients
September 24-26, 2027 – Stockholm, Sweden
Chairs: Michael Hudecek (Würzburg), Caron Jacobson (Boston), Marie José Kersten (Amsterdam)

Friday, September 24, 2027

08:15-08:25	**Welcome**	Conference Chairpersons
08:25-09:10	**Keynote lecture** **Chair: Stefan Mielke (Stockholm)**	
08:25-08:30	Introduction	Stephan Mielke (Stockholm)
08:30-09:00	Mechanisms of resistance to CAR-T: role of the tumor microenvironment	Michael Green (Houston)
09:00-09:10	Discussion	

SESSION I – Non-Hodgkin Lymphoma
Chair(s): TBA

09:10-09:30	Case-based lecture LBCL: high risk – first line	Jason Westin (Houston)
09:30-09:35	*Discussion*	
09:35-09:55	Case-based lecture LBCL: bispecific antibody therapy	Martine Chamuleau (Amsterdam)
09:55-10:00	*Discussion*	
10:00-10:20	Case-based lecture Primary and Secondary CNS localization	Caron Jacobson (Boston)
10:20-10:25	*Discussion*	
10:25-10:40	Interactive case Sequencing of CAR T vs bispecific antibodies	Catherine Thieblemont (Paris)*
10:40-11:10	*Panel discussion (an 8-minute brief oral communication may be added before the panel discussion)*	
11:10-11:40	***Coffee Break***	

SESSION II – Multiple myeloma
Chair(s): TBA

11:40-11:55	Interactive case High-risk MM	Francesca Gay (Turin)

11:55-12:15	Case-based lecture Multiple myeloma and bispecifics	Niels van de Donk (Amsterdam)
12:15-12:20	*Discussion*	
12:20-12:35	Interactive case Multiple myeloma and CAR-T	Hermann Einsele (Würzburg)
12:35-12:55	Case-based lecture Next generation of CARs and bispecifics in clinical trials	Eric Smith (Boston)
12:55-13:00	*Discussion*	

13:00-13:30 Panel discussion (an 8-minute brief oral communication may be added before the panel discussion)

13:30-15:25 Lunch

14:15-15:15 Possible slot for satellite symposium

15:25-18:15 DEBATE 1 – The future of CAR-T: in vivo or allo CAR-T?
Chair: TBA

Audience votes

15:25-15:40	In vivo CAR-T	Michael Hudecek (Würzburg)
15:40-15:55	Allo CAR-T	Frederick Locke (Tampa)*
15:55-16:05	*Discussion*	

Audience votes again

16:05-16:35 Coffee break

SESSION III – In vivo gene transfer
Chair(s): TBA

16:35-16:50	AAV	William Nyberg (San Francisco)*
16:50-16:55	*Discussion*	
16:55-17:10	Lentiviral vectors	Philippe Parone (Brussels)*
17:10-17:15	*Discussion*	
17:15-17:30	LNP	Matthias Stephan (Seattle)*
17:30-17:35	*Discussion*	
17:35-17:50	Bedside manufacturing	Ulrike Köhl (Leipzig)
17:50-17:55	*Discussion*	

17:55-18:35 Panel discussion (an 8-minute brief oral communication may be added before the panel discussion)

18:45-20:15 ***Poster Walks and Welcome Get-together for all***

Saturday, September 25, 2027

07:45-08:45 **3 Simultaneous Meet the Expert sessions**

08:45-09:45 ***Possible slot for satellite symposium***

SESSION IV – Novel indications of CAR-T cell therapy
Chair(s): TBA

09:45-10:00	CAR-T in AML	Sabrina Kraus (Würzburg)
10:00-10:05	*Discussion*	
10:05-10:20	CAR-T for MPN: the case for CALR as a target	Alex Rampotas (London)
10:20-10:25	*Discussion*	
10:25-10:40	Interactive case CAR-T in neurological autoimmune diseases	Anastasia Zekeridou (Rochester)*
10:40-10:55	Interactive case CAR-T in other autoimmune diseases: SLE, SSC	Melanie Hagen (Erlangen)*

10:55-11:25 *Panel discussion (an 8-minute brief oral communication may be added before the panel discussion)*

11:25-11:55 ***Coffee Break***

11:55-12:45 **ROUNDTABLE 1 – Global access issues in CAR-T and treatment with bispecific antibodies**
Chair: TBA

11:55-12:00	Asia	Michelle Poon (Singapore)
12:00-12:05	Europe	Elise Pennings (Amsterdam)
12:05-12:10	Africa	Candice Hendricks (Pretoria)
12:10-12:15	Central/South America	Lucila Nassif Kerbauy (Sao Paulo)
12:15-12:45	*Discussion*	

12:45-14:40 ***Lunch***

13:30-14:30 ***Possible slot for satellite symposium***

14:40-15:20 DEBATE 2 – CAR-T in multiple myeloma: first line or later lines?
Chair: TBA

Audience votes

14:40-14:55	Pro first line	Hermann Einsele (Würzburg)
14:55-15:10	Pro later lines	Monique Minnema (Utrecht)
15:10-15:20	*Discussion*	

Audience votes again

15:20-16:10 ROUNDTABLE 2 – Long term survivorship after CAR-T and bispecifics
Chair: TBA

15:20-15:25	Patient perspectives	Natacha Bolanos (Madrid)*
15:25-15:30	Survivorship programs	TBA
15:30-15:35	Long term infection risk	Kai Rejeski (Munich)
15:35-15:40	Prehabilitation and rehabilitation	Carmen Sanges (Würzburg)
15:40-16:10	*Discussion*	

16:10-16:40 Coffee break

SESSION V- Trials in progress in CAR-T
Chair(s): TBA

16:40-16:55	Dual antigen CARs in large cell lymphoma	Marie José Kersten (Amsterdam)
16:55-17:00	*Discussion*	
17:00-17:15	Gene edited products	Robert Chiesa (London)*
17:15-17:20	*Discussion*	
17:20-17:35	Armored CAR products	Jakub Svoboda (Philadelphia)
17:35-17:40	*Discussion*	
17:40-17:55	Alternative Immune cells	Katy Rezvani (Houston)
17:55-18:00	*Discussion*	

18:00-18:30 Panel discussion (an 8-minute brief oral communication may be added before the panel discussion)

Sunday, September 26, 2027

08:00-09:00 3 Simultaneous Meet the Expert Sessions

SESSION VI – How to optimize patients for response and toxicity after CAR-T and bispecifics treatments
Chair(s): TBA

09:10-09:30	Case-based lecture Resistance mechanisms to bispecific T cell engagers in MM	Holly Lee (Calgary)
09:30-09:35	*Discussion*	
09:35-09:55	Case-based lecture Holding and bridging strategies for lymphoma	Gloria Iacoboni (Barcelona)*
09:55-10:00	*Discussion*	
10:00-10:20	Case-based lecture Holding and bridging strategies for MM	Martin Kortüm (Würzburg)
10:20-10:25	*Discussion*	
10:25-10:40	Interactive case Infection and non-relapse mortality	Kai Rejeski (Munich)

10:40-11:10 Panel discussion (an 8-minute brief oral communication may be added before the panel discussion)

11:10-11:50 Coffee Break

11:50-12:35 Keynote lecture
Chair: Gunilla Enblad

11:50-11:55	Introduction	Gunilla Enblad (Uppsala)
11:55-12:25	Opportunities and cautions of the use of AI in advanced immunotherapies	Marco Ruella (Philadelphia)*
12:25-12:35	Discussion	
12:35-12:45	***Closing remarks***	Conference Chairpersons

MEETING CLOSURE

**pending confirmation*